Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis

Open Access 04-09-2024 | Checkpoint Inhibitors | Review

Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis

Authors: Qiao Zheng, Tiecheng Zhou, Weijun Ding

Published in: Clinical & Experimental Metastasis

Login to get access

Abstract

Although the intervention for triple-negative breast cancer (TNBC) patients has improved and survival time has increased, the combination of immune checkpoint inhibitors(ICIs) and PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors, PARPis) is still controversial. Previous studies revealed that the combined use of ICIs and PARPis led to increased antitumor activity. However, most of these combined regimens are nonrandomized controlled trials with small sample sizes. The purpose of this meta-analysis was to evaluate the efficacy and safety of ICIs combined with PARPis in patients with advanced or metastatic TNBC. The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched. The results including the objective remission rate (ORR), disease control rate (DCR), progression-free survival (PFS) and adverse events (AEs), were subjected to further analysis. Four studies involving 110 subjects were included in this meta-analysis. The combined ORR and DCR were 23.6% and 53.6%, respectively; while the ORR and DCR of BRCAmut patients were 38.1% and 71.4%, respectively. The median PFS of the patients was 4.29 months. As for safety, the most common AEs were nausea (49.0%), anemia (44.3%) and fatigue (40.6%). Most of them were grade 1 or 2, and the incidence of adverse events ≥ III was obviously low. Except for anemia, the incidence of AEs ≥ III was < 10%. This meta-analysis revealed that the combination of ICIs and PARPis has good efficacy and safety for advanced or metastatic TNBC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into Molecular classifications of Triple-negative breast Cancer: improving patient selection for treatment. Cancer Discov 9:176–198CrossRefPubMedPubMedCentral
3.
Laimito KR, Gámez-Pozo A, Sepúlveda J et al (2016) Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. E cancer Med Sci 10:632
4.
Bardia A, Mayer IA, Diamond JR et al (2017) Efficacy and safety of anti-trop-2 antibody drugconjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatictriple-negative breast cancer. J Clin Oncol 35:2141–2148CrossRefPubMedPubMedCentral
5.
O’Shaughnessy J, Schwartzberg L, Danso MA et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(34):3840–3847CrossRefPubMed
6.
Schmid P, Chui SY, Emens LA (2019) Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med 380(10):987–988PubMed
7.
Robson M, Im S-A, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533CrossRefPubMed
8.
Adams S, Schmid P, Rugo HS et al (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol 30(3):397–404CrossRefPubMed
9.
Dirix LY, Takacs I, Jerusalem G et al (2018) Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat 167(3):671–686CrossRefPubMed
10.
Emens LA, Cruz C, Eder JP et al (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5(1):74–82CrossRefPubMed
11.
Senkus-Konefka E, Domchek SM, Im SA et al (2018) 101 (PB-002): subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Eur J Cancer 92:S19–S20CrossRef
12.
Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763CrossRefPubMedPubMedCentral
13.
Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852–861CrossRefPubMed
14.
Huang J, Wang L, Cong Z et al (2015) The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(–/–) murine model of ovarian cancer. Biochem Biophys Res Commun 463(4):551–556CrossRefPubMed
15.
Jiao S, Xia W, Yamaguchi H et al (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression[J]. Clin Cancer Res 23(14):3711–3720CrossRefPubMedPubMedCentral
16.
Wang S, Sun K, Xiao Y et al (2018) Evaluation of niraparib in combination with anti-PD1/anti–PD-L1 in preclinical models[J]. Cancer Res 78(13):1724CrossRef
17.
Bound NT, Vandenberg CJ, Kartikasari AER et al (2022) Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: a focus on the immune system. Front Genet 13:886170CrossRefPubMedPubMedCentral
18.
Domchek SM, Postel-Vinay S, Im S-A et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA):an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21:1155–1164CrossRefPubMed
19.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation Criteria in Solid tumours: revised RECIST Guideline (Version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
20.
Elst P, Ahankour F, Tjalma W (2007) Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynecol Oncol 28(6):435–441
21.
Stang A (2010) Critical evaluation of the Newcastle Ottawa Scale for the Assessment of the quality of Nonrandomized studies in Meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed
22.
Yao H, Chen XY, Tan XD (2021) Efficacy and safety of apatinib in the treatment of Osteosarcoma: a single-arm Meta-analysis among Chinese patients. BMC Cancer 21(1):449CrossRefPubMedPubMedCentral
23.
Timothy A, Yap A, Bardia M, Dvorkin et al (2023) Avelumab Plus Talazoparib in patients with Advanced Solid tumors: the JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol 9(1):40–50CrossRef
24.
Friedlander M, Mileshkin L, Lombard J et al (2023) Pamiparib in combination with tislelizumab in patients with advanced solid tumors: results from the dose-expansion stage of a multicenter, open-label, phase I trial. Br J Cancer 129(5):797–810CrossRefPubMedPubMedCentral
25.
Tira J, Tan S, Sammons Y-H, Im et al (2024) Phase II DORA Study of Olaparib with or without Durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated Advanced Triple-negative breast Cancer. Clin Cancer Res 30(7):1240–1247CrossRef
26.
Vinayak S, Tolaney SM, Schwartzberg S et al (2019) Open-label clinical trial of Niraparib Combined with Pembrolizumab for treatment of Advanced or Metastatic Triple-negative breast Cancer. JAMA Oncol 5(8):1132–1140CrossRefPubMedPubMedCentral
27.
Luchini C, Stubbs B, Solmi M et al (2017) Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal 5(4):80–84CrossRef
28.
29.
Wu Z, Cui P, Tao H et al (2021) The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol 15:1179554921996288CrossRefPubMedPubMedCentral
30.
Jiao S, Xia W, Yamaguchi H et al (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711–3720CrossRefPubMedPubMedCentral
31.
Wang Y, Zheng K, Xiong H et al (2021) PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer. Front Immunol 12:762989CrossRefPubMedPubMedCentral
32.
Strickland KC, Howitt BE, Shukla SA et al (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7:13587–13598CrossRefPubMedPubMedCentral
33.
Wang PF, Chen Y, Song SY et al (2017) Immune-related adverse events Associated with Anti-PD-1/PD-L1 treatment for malignancies: a Meta-analysis. Front Pharm 8:730CrossRef
34.
Dammeijer F, van Gulijk M, Mulder EE et al (2020) The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38:685–700CrossRefPubMed
35.
Bagchi S, Yuan R, Engleman EG (2021) Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249CrossRefPubMed
36.
Zhang M, Song J, Yang H et al (2022) Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Acta Oncol 61:1105–1115CrossRefPubMed
Metadata
Title
Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis
Authors
Qiao Zheng
Tiecheng Zhou
Weijun Ding
Publication date
04-09-2024
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-024-10307-0